SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-16-028688
Filing Date
2016-11-09
Accepted
2016-11-09 16:49:42
Documents
65
Period of Report
2016-09-30

Document Format Files

Seq Description Document Type Size
1 NAVB-Q3-20160930 navb-10q_20160930.htm 10-Q 1812166
2 EX-31.1 navb-ex311_7.htm EX-31.1 10214
3 EX-31.2 navb-ex312_75.htm EX-31.2 10201
4 EX-32.1 navb-ex321_6.htm EX-32.1 5772
5 EX-32.2 navb-ex322_74.htm EX-32.2 5751
  Complete submission text file 0001564590-16-028688.txt   7604023

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT navb-20160930.xml EX-101.INS 1799317
7 XBRL TAXONOMY EXTENSION SCHEMA navb-20160930.xsd EX-101.SCH 48487
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20160930_cal.xml EX-101.CAL 53775
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20160930_def.xml EX-101.DEF 214316
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20160930_lab.xml EX-101.LAB 398075
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20160930_pre.xml EX-101.PRE 336148
Mailing Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017
Business Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 161984889
SIC: 2835 In Vitro & In Vivo Diagnostic Substances